Search Results - Idbaih, A

Glioblastoma targeted therapy: updated approaches from recent biological insights by Touat, M., Idbaih, A., Sanson, M., Ligon, K. L.

Get full text Get full text Get full text

P04.10 Chains of magnetosomes induce full destruction of intracranial U87-Luc and subcutaneous GL-261 glioma in mice under the application of an alternating magnetic field by Alphandery, E, Idbaih, A, Adam, C, Delattre, J, Schmitt, C, Guyot, F, Chebbi, I

Get full text Get full text

P04.14 IDH1 MUTATION IN LOW-GRADE GLIOMAS RELATED TO EPILEPSY AS INITIAL SYMPTOM by Duran-Peña, A., Mokhtari, K., Marie, Y., Alentorn, A., Delattre, J., Idbaih, A., Sanson, M., Vecht, C.

Get full text Get full text

P17.08 RENAL THROMBOTIC MICROANGIOPATHY INDUCED BY BEVACIZUMAB IN HIGH GRADE GLIOMA PATIENTS - ABOUT SIX CASES by Blonski, M., Simon, L., Houillier, C., Idbaih, A., Wittwer, B., Beauchesne, P., Hoang-Xuan, K., Taillandier, L.

Get full text Get full text

P10.14 Long-term impact of Temozolomide on 1p19q codeleted oligodendrogliomas growth kinetics by Izquierdo, C., Alentorn, A., Simó, M., Idbaih, A., Ricard, D., Kaloshi, G., Bruna, J., Honnorat, J., Delattre, J., Ducray, F.

Get full text Get full text

OS5.5 Characteristics of high-grade gliomas with H3 G34 mutation in adults by Picart, T, Barritault, M, Tabouret, E, Idbaih, A, Izquierdo Gracia, C, Poncet, D, Honnorat, J, Meyronet, D, Guyotat, J, Ducray, F

Get full text Get full text

P05.05 Safety and feasibility of temporary blood-brain barrier disruption with the SonoCloud-1/3 implantable ultrasound device in recurrent glioblastoma by Idbaih, A, Canney, M, Bouchoux, G, Desseaux, C, Vignot, A, Lafon, C, Chapelon, J, Delattre, J, Belin, L, Carpentier, A

Get full text Get full text

OS11.3 Machine learning for better prognostic stratification and driver genes identification in 1p/19q-codeleted grade III gliomas by Rosenberg, S., Dehais, C., Ducray, F., Alentron, A., Tanguy, M., De Reyneis, A., Elarouci, N., Figarella-Branger, D., Delattre, J., Idbaih, A.

Get full text Get full text

EH1.3 EORTC 26101 phase III trial exploring the combination of bevacizumab and lomustine versus lomustine in patients with first progression of a glioblastoma by van den Bent, M., Gorlia, T., Bendszus, M., Sahm, F., Domont, J., Idbaih, A., Platten, M., Weller, M., Golfoinopoulos, V., Wick, W.

Get full text Get full text

P01.148 Intra-tumor heterogeneity analysis of low-grade gliomas. A POLA Network study by Alentorn, A, Labreche, K, Dehais, C, Carpentier, C, Ducray, F, Mokhtari, K, Figarella-Branger, D, Sanson, M, Delattre, J, Idbaih, A

Get full text Get full text

P06.18 DNA methylation distance score in lower-grade gliomas has prognostic value: a POLA network study by Alentorn, A., Kamoun, A., Ducray, F., Dehais, C., Mokhtari, K., Uro-Coste, E., Figarella-Branger, D., Delattre, J., Idbaih, A., Sanson, M.

Get full text Get full text

P06.19 TERT promoter mutation is an independent prognostic factor in 1p/19q co-deleted oligodendrogliomas: a POLA network study by Alentorn, A., Carpentier, C., Labreche, K., Ducray, F., Dehais, C., Mokhtari, K., Uro-Coste, E., Figarella-Branger, D., Delattre, J., Idbaih, A.

Get full text Get full text

O10.02 MITOTIC INDEX, MICROVASCULAR PROLIFERATION AND NECROSIS DEFINE THREE GROUPS OF 1P/19Q CO-DELETED ANAPLASTIC OLIGODENDROGLIOMAS ASSOCIATED WITH DIFFERENT GENOMIC ALTERATIONS by Figarella-Branger, D., Mokhtari, K., Dehais, C., Jouvet, A., Uro-Coste, E., Colin, C., Carpentier, C., Ducray, F., Idbaih, A., Network, French POLA

Get full text Get full text

P09.14 Clonal and subclonal evolution of 1p/19q co-deleted oligodendrogliomas by Alentorn, A., Daniau, M., Royer-Perron, L., Labreche, K., Duran-Pena, A., Marie, Y., Hoang-Xuan, K., Sanson, M., Delattre, J., Idbaih, A.

Get full text Get full text

P20.01 MEVITEM: A European, randomized, open-label Phase I/II study of vismodegib in combination with temozolomide versus temozolomide alone in adult patients with recurrent or ref... by Frappaz, D., Meyronnet, D., Garin, G., Laigle-Donadey, F., Le Rhun, E., Bonneville-Levard, A., Frenel, J., Idbaih, A., Gourmelon, C., Chinot, O.

Get full text Get full text

P11.59 Integrin a5 heterogeneous expression in glioblastoma is related to glioma stem cell subpopulations by Dontenwill, M, Mercier, M, Gillmann, G, Reita, D, Lelong-Rebel, I, Noulet, F, Idbaih, A, Herold-Mende, C, Bagnard, D, Spenlé, C, Martin, S

Get full text Get full text

OS8.5 How to assess meningioma therapy activity: The CEVOREM independent central review experience by GRAILLON, T, Colin, T, Peyrière, H, Peyre, M, Tabouret, E, Campello, C, Idbaih, A, Boucekine, M, Figarella-Branger, D, Kalamarides, M, Dufour, H, Sanson, M, Chinot, O

Get full text Get full text

P17.01 CHROMOSOME ARM 9P LOSS OF HETEROZYGOSITY IS A MARKER OF SHORTER SURVIVAL IN 1P/19Q CO-DELETED ANAPLASTIC OLIGODENDROGLIOMA. A POLA NETWORK STUDY by Alentorn, A., Dehais, C., Carpentier, C., Mokhtari, K., Ducray, F., Figarella-Branger, D., Delattre, J., Idbaih, A., (POLA)”, POLA Network “Prise en charge des OLigodendrogliomes Anaplasiques

Get full text Get full text

OS5.2 Health-Related Quality of Life (HRQoL) in patients with progressive glioblastoma treated with combined bevacizumab and lomustine versus lomustine only (randomized phase III E... by Taphoorn, M. J. B., Bottomley, A., Coens, C., Reijneveld, J. C., Gorlia, T., Brandes, A. A., Domont, J., Idbaih, A., van den Bent, M. J., Wick, W.

Get full text Get full text

OS5.7 First results of the randomized phase II TAVAREC trial on temozolomide with or without bevacizumab in 1p/19q intact 1st recurrence grade II and III glioma by Idbaih, A., Clement, P. M., Vos, F. Y. F., Platten, M., Mulholland, P., Taphoorn, M. J. B., Lewis, L., Golfinopoulos, V., Gorlia, T., van den Bent, M. J.

Get full text Get full text